Budesonide/glycopyrronium/formoterol fumarate triple therapy prevents pulmonary hypertension in a COPD mouse model via NFκB inactivation
Abstract Background Chronic obstructive pulmonary disease (COPD) is a health problem that results in death, commonly due to the development of pulmonary hypertension (PH). Here, by utilizing a mouse model of intratracheal elastase-induced emphysema that presents three different phases of COPD, we so...
Main Authors: | Ratoe Suraya, Tatsuya Nagano, Gusty Rizky Teguh Ryanto, Wiwin Is Effendi, Daisuke Hazama, Naoko Katsurada, Masatsugu Yamamoto, Motoko Tachihara, Noriaki Emoto, Yoshihiro Nishimura, Kazuyuki Kobayashi |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-06-01
|
Series: | Respiratory Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12931-022-02081-y |
Similar Items
-
Comparative efficacy and safety of glycopyrronium/formoterol fixed-dose combination versus glycopyrronium monotherapy in patients with moderate-to–severe COPD
by: Sundeep Salvi, et al.
Published: (2022-01-01) -
Cost-Effectiveness of Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: United Kingdom Analysis Using the ETHOS Study
by: de Nigris E, et al.
Published: (2022-11-01) -
The double bronchodilation era: new capabilities in a new drug delivery device
by: E. A. Orlova, et al.
Published: (2022-04-01) -
TRITRIAL: The Impact of Fixed Triple Therapy with Beclometasone/Formoterol/Glycopyrronium on Health Status and Adherence in Chronic Obstructive Pulmonary Disease in an Italian Context of Real Life
by: Richeldi L, et al.
Published: (2024-02-01) -
Some aspects of application of the combination of formoterol and budesonide: what is changed?
by: A. A. Vizel, et al.
Published: (2019-12-01)